• Users Online: 261
  • Print this page
  • Email this page
Year : 2018  |  Volume : 3  |  Issue : 4  |  Page : 132-137

The traditional Chinese medication nuanxin capsule aids in the treatment of chronic heart failure

1 Shenzhen Research Institute of Shandong University, Shenzhen, Guangdong; Shandong University Qilu Hospital and School of Basic Medical Sciences, Shandong University, Jinan, Shandong, China
2 Shandong University Qilu Hospital and School of Basic Medical Sciences, Shandong University, Jinan, Shandong, China
3 Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, Shandong, China

Correspondence Address:
Panpan Hao
Shenzhen Research Institute of Shandong University, Shenzhen 518057, Guangdong; Department of Cardiology, The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, Shandong University Qilu Hospital, Jinan 250012, Shandong
Zhongwen Zhang
Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan 250014, Shandong
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/cp.cp_33_18

Get Permissions

Background: Nuanxin capsule is a standardized Chinese herbal medication that is commonly used alongside conventional treatment for chronic heart failure (CHF) in China. However, whether or not it improves outcomes is unknown due to the lack of high-quality randomized controlled trials (RCTs). Methods: We did a patient-level pooled-analysis of 14 RCTs in which 1112 CHF patients from nine medical centers in China were enrolled. These patients were randomly assigned to treatment with Nuanxin capsule in addition to conventional treatment, conventional treatment with placebo, or conventional treatment alone. Our primary outcomes were mortality and rehospitalization rate. Secondary outcomes included New York Heart Association (NYHA) functional classification, plasma brain natriuretic peptide, 6-min walking distance, echocardiographic parameters, and noninvasive hemodynamic parameters. Results: Treatment with Nuanxin capsule significantly decreased mortality (risk ratio [RR] = 0.30, 95% confidence interval [CI] 0.15–0.58, P = 0.0003, I2 = 0%) and rehospitalization rate (RR = 0.47, 95% CI 0.36–0.62, P < 0.00001, I2 = 0%). Nuanxin capsule therapy also had favorable effects on secondary outcomes. Fail-safe = 0.05 value for NYHA functional classification showed negligible publication bias, with a very low probability that future studies can change the current conclusion. Conclusion: We provided conclusive evidence for the beneficial effects of Nuanxin capsule in patients with CHF.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded78    
    Comments [Add]    

Recommend this journal